Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat

HIV Clinical Trials

Volumn 10, Issue 5, 2009, Pages 314-319

  Tungsiripat, Marisa ^a   O'Riordan, Mary Ann ^b   Storer, Norma ^b   Harrill, Danielle ^b   Ganz, Jason ^c   Libutti, Daniel ^d   Gerschenson, Mariana ^d   McComsey, Grace A ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

DEXA; Lipoatrophy; Lipodystrophy

Indexed keywords

MITOCHONDRIAL DNA;

ADULT; AGED; ARTICLE; BODY FAT; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; LIMB; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SELF EVALUATION; SUBCUTANEOUS FAT; VALIDATION PROCESS; VALIDITY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; CROSS-SECTIONAL STUDIES; DNA, MITOCHONDRIAL; EXTREMITIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; QUESTIONNAIRES; STATISTICS AS TOPIC; SUBCUTANEOUS FAT;

EID: 70450197208     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1005-314     Document Type: Article

References (22)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51-58.
2. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS. 2000;14(13):1935-1942.
3. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351(9106): 871-875.
4. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288(2):207-215.
5. Dukers NH, Stolte IG, Albrecht N, Coutinho RA, De Wit JB. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS. 2001;15(6):812-813.
6. Duran S, Saves M, Spire B, et al. Failure to maintain longterm adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441-2444.
7. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunoDeficiency virusinfected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38(2):263-270.
8. Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2001;26(5):443-448.
9. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14(10):1309-1316.
10. Prior BM, Cureton KJ, Modlesky CM, et al. In vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J Appl Physiol. 1997;83(2):623-630.
11. Salamone LM, Fuerst T, Visser M, et al. Measurement of fat mass using DEXA: a validation study in elderly adults. J Appl Physiol. 2000;89(1):345-352.
12. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 2005;19(1):15-23.
13. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIVinfected individuals with peripheral lipoatrophy. AIDS. 2001;15(14):1801-1809.
14. Hoy JF, Gahan ME, Carr A, et al. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIVinfected patients with lipoatrophy randomized to receive abacavir. J Infect Dis. 2004;190(4):688-692.
15. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case defi nition score. J Acquir Immune Defic Syndr. 2003;33(5):571-576.
16. Podzamczer D, Ferrer E, Martinez E, Team AS. How much fat loss is needed for lipoatrophy to become clinically evident? Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston. MA. Abstract 941.
17. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr. 2003;32(4):370-374.
18. Funk E, Brissett AE, Friedman CD, Bressler FJ. HIVassociated facial lipoatrophy: establishment of a validated grading scale. Laryngoscope. 2007;117(8):1349-1353.
19. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005;52(2):233-239.
20. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40(2):121-131.
21. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther. 2005;10(Suppl 2):M83-89.
22. McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr. 2007:1031.